Ultragenyx Reports Second Quarter 2015 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Ultragenyx Pharma (RARE) Misses Q2 EPS by 20c
August 13, 2015 4:36 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($0.83), $0.20 worse than the analyst estimate of ($0.63).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More